#	Pagina
attuale pagina	/open-h2020/projects/201570/index.html

Opendata, web and dolomites

THERAGEL

Development of a chemotherapeutic gel for glioblastoma multiforme treatment

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

THERAGEL project word cloud

Explore the words cloud of the THERAGEL project. It provides you a very rough idea of what is the project "THERAGEL" about.

therapeutics nanotheranostics agent polymer therapeutic context continuous nanotechnology manufacturing combination nanoparticle nanoparticles clinical free polymeric advanced administered leads selective multiforme aggressive horizon tunable cargo translation expertise constitutes payloads composition treatment chemotherapy treatments strategy oncology ineffective individual depots glioblastoma diagnostic drug depending agents themes theranostic groups pi technologies possible chance near brain cancer profile biomaterials materials systemically nanomedicines 2020 comprise multidisciplinary injectable solutions gated therapies chemotherapeutic networking molecules opportunity release local host industrial six combining form imaging therapy direction theragel cells components

Project "THERAGEL" data sheet

The following table provides information about the project.

Coordinator	THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN Organization address address: College Green city: DUBLIN postcode: 2 website: www.tcd.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	https://pharmacy.tcd.ie/staff/ruiz-hernandez-cv.php
Total cost	175˙866 €
EC max contribution	175˙866 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2015
Funding Scheme	MSCA-IF-EF-ST
Starting year	2016
Duration (year-month-day)	from 2016-04-01 to 2018-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN Organization address address: College Green city: DUBLIN postcode: 2 website: www.tcd.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	coordinator	87˙933.00
2	ROYAL COLLEGE OF SURGEONS IN IRELAND ROYAL COLLEGE OF SURGEONS IN IRELAND Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 website: www.rcsi.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	participant	87˙933.00

Map

Project objective

Advanced nanotechnology-based materials offer new solutions to the challenges associated with the non-specific delivery of therapeutics that leads to ineffective treatments, especially in oncology. Currently, both therapeutic and diagnostic molecules are administered systemically, increasing the likelihood of unwanted side effects. THERAGEL will develop a novel delivery system that enables selective, targeted local delivery of therapeutics and imaging agents. Specifically, I will use this delivery system to design a therapy for the treatment of glioblastoma multiforme, the most aggressive form of brain cancer. THERAGEL will comprise a unique combination of advanced injectable polymeric depots and targeted nanoparticles with both chemotherapeutic and imaging agent payloads (‘theranostic’ nanoparticle). The polymeric depots will provide a continuous release of free chemotherapeutic drug, with a tunable profile depending on the polymer composition, and cancer-targeted nanoparticles that will release the theranostic cargo only after selective uptake by cancer cells. THERAGEL will advance the state of the art in nanomedicines through advances to the individual components of the developed delivery system. This proposal represents a unique opportunity in the context of nanotheranostics for tailored chemotherapy, and means a significant step towards its clinical translation. The technologies developed will address three out of the six Horizon 2020 Key Enabling Technologies themes, which are a key part of the programme funding strategy: Nanotechnology, Advanced Biomaterials and Advanced Manufacturing technologies. This research constitutes a highly multidisciplinary approach with large impact in near future advanced therapies and with a great chance for collaboration and networking between European research groups and industrial partners. Combining my expertise in gated-materials with the host PI’s delivery systems development experience will make this new direction possible

Publications

List of publications.
year	authors and title	journal	last update
2018	L. Nam, C. Coll, L. Erthal, C. de la Torre, D. Serrano, R. MartÃnez-MÃ¡Ã±ez, M. Santos-MartÃnez, E. Ruiz-HernÃ¡ndez Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme published pages: 779, ISSN: 1996-1944, DOI: 10.3390/ma11050779	Materials 11/5	2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAGEL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAGEL" are provided by the European Opendata Portal: CORDIS opendata.